Source link : https://www.newshealth.biz/health-news/aumolertinib-promising-maintenance-therapy-in-egfr-nsclc/
SAN DIEGO — Treatment with the estimated glomerular filtration rate (EGFR) tyrosine kinase inhibitor (TKI) aumolertinib after chemoradiation was associated significant improvement in progression-free survival compared with placebo in patients with unresectable stage III EGFR-mutant non–small cell lung cancer (NSCLC). The preplanned interim analysis of the phase 3 POLESTAR study also indicated that aumolertinib has […]
Author : News Health
Publish date : 2024-09-11 12:51:49
Copyright for syndicated content belongs to the linked Source.